Evidence map›Paper›PMID 39316135›Full record

ArticleCalcified tissue international2024

Early-Onset Osteoporosis: Molecular Analysis in Large Cohort and Focus on the PLS3 Gene.

Maxence Mancini, Roland Chapurlat, Bertrand Isidor, Marine Desjonqueres, Guillaume Couture, Pascal Guggenbuhl, Régis Coutant, Salima El Chehadeh, Mélanie Fradin, Aline Frazier and 15 more

Abstract read
PubMed Publisher
In one paragraph

Article in Calcified tissue international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Maxence ManciniBiochemistry and Molecular Genetics Department, Lariboisière Hospital, AP-HP, Paris, France.
Roland ChapurlatRheumatology and Bone Pathology Department, Inserm UMR 1033, Université de Lyon, Edouard Herriot Hospital, HCL, Lyon, France.
Bertrand IsidorMedical Genetics Department, CHU de Nantes, Hôtel Dieu Hospital, Nantes, France.
Marine DesjonqueresNephrology - Rheumatology - Dermatology Paediatric Department, Edouard Herriot Hospital, HCL, Lyon, France.
Guillaume CoutureEndocrine, Bone Diseases and Genetics Unit, Rheumatology Department, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, ERN BOND, OSCAR Network, University Hospital, RESTORE, INSERM U1301, Toulouse, France.
Pascal GuggenbuhlRheumatology Department, CHU Rennes, Sud Hospital, Rennes, France.
Régis CoutantDepartment of Paediatrics and Endocrinology, CHU d'Angers, Angers, France.
Salima El ChehadehMedical Genetics Department, Institut de Génétique Médicale d'alsace, CHU de Strasbourg, Strasbourg, France.
Mélanie FradinClinical Genetics Department, CHU Rennes, Sud Hospital, Rennes, France.
Aline FrazierRheumatology Department, Inserm 1132, Univsersité Paris-Cité, Lariboisière Hospital, AP-HP, Paris, France.
Alice GoldenbergMedical Genetics Department, Charles- Nicolle Hospital, CHU de Rouen, Rouen, France.
Pascaline GuillotRheumatology Department, CHU de Nantes, Hôpital Hôtel Dieu, Nantes, France.
Eugénie KoumakisRheumatology Department, Cochin Hospital, AP-HP, Paris, France.
Nadia Mehsen-CêtreRheumatology Department, CHU Pellegrin, Bordeaux, France.
Massimiliano RossiMedical Genetics Department, Edouard Herriot Hospital, HCL, Lyon, France.
Élise SchaeferMedical Genetics Department, Institut de Génétique Médicale d'alsace, CHU de Strasbourg, Strasbourg, France.
Sabine SigaudyMedical Genetics Department, CHU de Marseille, Timone Hospital, Marseille, France.
Valérie Porquet-BordesEndocrine, Bone Diseases and Genetics Unit, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, ERN BOND, OSCAR Network, Paediatric Research Unit, Children's Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Toulouse, France.
Élisabeth FontangesRheumatology and Bone Pathology Department, Inserm UMR 1033, Université de Lyon, Edouard Herriot Hospital, HCL, Lyon, France.
Pauline LetardMedical Genetics Department, CHU de Poitiers, Poitiers, France.
Thomas EdouardEndocrine, Bone Diseases and Genetics Unit, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, ERN BOND, OSCAR Network, Paediatric Research Unit, Children's Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Toulouse, France.
Rose-Marie JavierRheumatology Department, CHU de Strasbourg, Hautepierre Hospital, Strasbourg, France.
Martine Cohen-SolalRheumatology Department, Inserm 1132, Univsersité Paris-Cité, Lariboisière Hospital, AP-HP, Paris, France.
Thomas Funck-BrentanoRheumatology Department, Inserm 1132, Univsersité Paris-Cité, Lariboisière Hospital, AP-HP, Paris, France.
Corinne ColletRare Disease Genomic Medicine Department, CHU Necker-Enfants Malades, INSERM UMR1163, Institut Imagine, Université Paris-Cité, Paris, France. corinne.collet@aphp.fr.ORCID 0000-0001-6990-863X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis is a skeletal disorder characterized by abnormal bone microarchitecture and low bone mineral density (BMD), responsible for an increased risk of fractures and skeletal fragility. It is a common pathology of the aging population. However, when osteoporosis occurs in children or young adults, it strongly suggests an underlying genetic etiology. Over the past two decades, several genes have been identified as responsible for this particular kind of considered monogenic early-onset osteoporosis (EOOP) or juvenile osteoporosis, the main ones being COL1A1, COL1A2, LRP5, LRP6, WNT1, and more recently PLS3. In this study, the objective was to characterize a large cohort of patients diagnosed with primary osteoporosis and to establish its diagnosis yield. The study included 577 patients diagnosed with primary osteoporosis and its diagnosis yield was established. To this end, next-generation sequencing (NGS) of a panel of 21 genes known to play a role in bone fragility was carried out. A genetic etiology was explained in about 18% of cases, while the others remain unexplained. The most frequently identified gene associated with EOOP is LRP5, which was responsible for 8.2% of the positive results (47 patients). As unexpected, 17 patients (2.9%) had a variant in PLS3 which encodes plastin 3. Alterations of PLS3 are associated with dominant X-linked osteoporosis, an extremely rare disease. Given the rarity of this disease, we focused on it. It was observed that males were more affected than females, but it is noteworthy that three females with a particularly severe phenotype were identified. Of these three, two had a variant in an additional gene involved in EOP, illustrating the probable existence of digenism. We significantly increase the number of variants potentially associated with EOOP, especially in PLS3. The results of our study demonstrate that molecular analysis in EOOP is beneficial and useful.

Indexed as

Membrane GlycoproteinsMicrofilament ProteinsOsteoporosisAdolescentAdultAge of OnsetBone DensityChildChild, PreschoolCohort StudiesFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedMutationMembrane GlycoproteinsMicrofilament ProteinsplastinDigenismEarly-onset osteoporosisLRP5PLS3

Identifiers

PMID39316135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.